Functional characterization of Filamin A interacting protein 1-like, a novel candidate for antivascular cancer therapy

Mijung Kwon, Engy Hanna, Dominique Lorang, Mei He, John S. Quick, Asha Adem, Christina Stevenson, Joon Yong Chung, Stephen M. Hewitt, Enrique Zudaire, Dominic Esposito, Frank Cuttitta, Steven K. Libutti

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Inhibiting angiogenesis has become a major therapeutic strategy for cancer treatment. To identify common intracellular mediators, we previously analyzed gene expression profiles of endothelial cells after treatment with angiogenesis inhibitors. Filamin A interacting protein 1-like (FILIP1L; previously known as down-regulated in ovarian cancer 1) was identified as one of the genes up-regulated in endothelial cells in response to these inhibitors. However, the expression and function of FILIP1L protein is uncharacterized. Here, we provide the first description of the expression and specific subcellular localization of FILIP1L protein in human tissue. Overexpression of FILIP1L resulted in inhibition of cell proliferation and migration and increased apoptosis. In addition, overexpression of FILIP1L truncation mutants showed differential antiproliferative activity. A COOH terminal truncation mutant (FILIP1LΔC103) was more potent than wild-type FILIP1L in mediating this activity. Targeted expression of FILIP1LΔC103 in tumor vasculature inhibited tumor growth in vivo. Overall, these findings suggest that the novel protein FILIP1L may be an important mediator of the effects of angiogenesis inhibitors and that FILIP1L has the potential to be an antivascular reagent for cancer therapy.

Original languageEnglish (US)
Pages (from-to)7332-7341
Number of pages10
JournalCancer research
Issue number18
StatePublished - Sep 15 2008
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Functional characterization of Filamin A interacting protein 1-like, a novel candidate for antivascular cancer therapy'. Together they form a unique fingerprint.

Cite this